Painreform Ltd Stock Price, News & Analysis

PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, will have CEO Ilan Hadar present at the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. Hadar's presentation is scheduled for April 26th at 1:30 PM ET. The summit will feature over 40 presentations from public companies, with opportunities for attendees to engage in one-on-one meetings and networking events. PainReform is focused on reformulating established therapeutics, with PRF-110 as its lead product targeting post-operative pain relief. This product is currently in Phase III clinical trials and utilizes a proprietary drug-delivery system designed for extended pain relief. For more information about the summit, visit puertorico.srax.com.

PainReform Ltd. (Nasdaq: PRFX) has completed the first part of its Phase 3 clinical trial for PRF-110, enrolling 15 patients undergoing unilateral bunionectomy. This trial aims to evaluate the analgesic efficacy and safety of PRF-110, which is applied directly into the surgical site for extended pain relief. The initial phase provided training for surgeons on optimal application methods, and results on pharmacokinetics will be available in May 2023. The second phase will involve approximately 400 patients across seven sites, comparing PRF-110 with ropivacaine and placebo.

PainReform Ltd. (Nasdaq: PRFX) provided a business update for 2022, marking significant advancements in the clinical development of PRF-110, its lead drug candidate targeting post-operative pain relief. The initiation of a Phase 3 clinical trial for bunionectomy has commenced, focusing on a safety pharmacokinetic study with 15 patients in Texas, with results expected in May 2023. Following this, a larger trial involving 400 patients will evaluate pain reduction over 72 hours. Financially, the company recorded a net loss of approximately $8.8 million and has approximately $10.2 million in cash as of December 31, 2022.

PainReform Ltd. (Nasdaq: PRFX) has initiated a Phase 3 clinical trial for its lead drug candidate, PRF-110, targeting post-operative pain relief following bunionectomy. The trial comprises two parts: an open-label safety study with 15 patients, followed by a double-blind study with around 400 patients across multiple sites. PRF-110 aims to provide localized, extended analgesia without the need for repeated dosing, addressing the opioid crisis. Initial pharmacokinetic data is expected in May 2023, with potential to capture a share in the $12 billion post-operative pain market if successful.

PainReform Ltd. (Nasdaq: PRFX) announced on February 7, 2023, that it has received a 180-day extension from Nasdaq to regain compliance with the minimum $1 bid price per share requirement, giving it until August 7, 2023. The company previously failed to maintain this bid price for 30 consecutive trading days, first notified on August 10, 2022. To regain compliance, PRFX must achieve a closing bid price of $1 or higher for 10 consecutive trading days before the deadline. PainReform focuses on reformulating established therapeutics, with its lead product, PRF-110, targeting post-operative pain relief.

PainReform Ltd. (Nasdaq: PRFX) provided a business update for Q3 2022, focusing on PRF-110, a product for post-operative pain relief following bunionectomy surgery. The company made enhancements to its manufacturing process, leading to delays in starting the Phase 3 clinical trial but aims to rectify the issue. As of September 30, 2022, it reported $12.9 million in cash, supporting upcoming milestones. R&D expenses increased to $2.5 million, while net loss rose slightly to $5.6 million. PainReform plans to initiate another Phase 3 trial for pain treatment in hernia repair surgery.

PainReform Ltd. (Nasdaq: PRFX) announced a delay in the Phase 3 trial for PRF-110 due to manufacturing issues, which are expected to enhance efficiency and scalability. CEO Ilan Hadar highlighted optimism based on prior Phase 2 results and the potential of PRF-110 in the $12 billion post-operative pain market as a safer alternative to opioids. The company remains committed to providing updates on the trial's start date as they progress.